Published in Am J Pathol on September 01, 1998
Prognostic value of cell-cycle markers in ocular adnexal lymphoma: an assessment of 230 cases. Graefes Arch Clin Exp Ophthalmol (2003) 1.18
Tumor suppressor gene methylation in follicular lymphoma: a comprehensive review. Mol Cancer (2006) 1.00
Cytogenetic alterations affecting BCL6 are predominantly found in follicular lymphomas grade 3B with a diffuse large B-cell component. Am J Pathol (2004) 0.96
Comparative genome-scale analysis of gene expression profiles in T cell lymphoma cells during malignant progression using a complementary DNA microarray. Am J Pathol (2001) 0.92
Overall survival in aggressive B-cell lymphomas is dependent on the accumulation of alterations in p53, p16, and p27. Am J Pathol (2001) 0.91
Prognostic value of genomic alterations in minimal residual cancer cells purified from the blood of breast cancer patients. Br J Cancer (2000) 0.90
Different incidence and pattern of p15INK4b and p16INK4a promoter region hypermethylation in Hodgkin's and CD30-Positive non-Hodgkin's lymphomas. Am J Pathol (2002) 0.86
p16(INK4a) gene alterations are frequent in lesions of mycosis fungoides. Am J Pathol (2000) 0.86
Nitric oxide: perspectives and emerging studies of a well known cytotoxin. Int J Mol Sci (2010) 0.84
Colorectal cancer DNA methylation marker panel validated with high performance in Non-Hodgkin lymphoma. Epigenetics (2013) 0.83
Epstein-Barr virus and p16INK4A methylation in squamous cell carcinoma and precancerous lesions of the cervix uteri. J Korean Med Sci (2005) 0.80
Expression of p16/INK4a in posttransplantation lymphoproliferative disorders. Am J Pathol (2000) 0.79
Nucleolar p14(ARF) overexpression in Reed-Sternberg cells in Hodgkin's lymphoma: absence of p14(ARF)/Hdm2 complexes is associated with expression of alternatively spliced Hdm2 transcripts. Am J Pathol (2002) 0.76
Cell kinetics and cell cycle regulation in lymphomas. J Clin Pathol (2002) 0.75
Loss of P16 Protein Expression and Its Association with Epstein-Barr Virus LMP-1 Expression in Hodgkin's Lymphoma. Iran J Cancer Prev (2013) 0.75
Plasma DNA methylation of p16 and shp1 in patients with B cell non-Hodgkin lymphoma. Int J Clin Oncol (2017) 0.75
A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group. Blood (1994) 21.00
Rapid and sensitive detection of point mutations and DNA polymorphisms using the polymerase chain reaction. Genomics (1989) 19.10
A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4. Nature (1993) 13.68
Inhibitors of mammalian G1 cyclin-dependent kinases. Genes Dev (1995) 13.66
A cell cycle regulator potentially involved in genesis of many tumor types. Science (1994) 13.00
p15INK4B is a potential effector of TGF-beta-induced cell cycle arrest. Nature (1994) 10.95
5' CpG island methylation is associated with transcriptional silencing of the tumour suppressor p16/CDKN2/MTS1 in human cancers. Nat Med (1995) 9.10
Deletions of the cyclin-dependent kinase-4 inhibitor gene in multiple human cancers. Nature (1994) 6.06
Germline p16 mutations in familial melanoma. Nat Genet (1994) 5.59
Frequent somatic mutations and homozygous deletions of the p16 (MTS1) gene in pancreatic adenocarcinoma. Nat Genet (1994) 4.63
Frequency of homozygous deletion at p16/CDKN2 in primary human tumours. Nat Genet (1995) 3.76
Joining the complex: cyclin-dependent kinase inhibitory proteins and the cell cycle. Cell (1994) 3.07
Inhibition of ras-induced proliferation and cellular transformation by p16INK4. Science (1995) 2.42
Distinct patterns of inactivation of p15INK4B and p16INK4A characterize the major types of hematological malignancies. Cancer Res (1997) 2.12
Differential expression and cell cycle regulation of the cyclin-dependent kinase 4 inhibitor p16Ink4. Cancer Res (1994) 1.88
A novel p16INK4A transcript. Cancer Res (1995) 1.74
Homozygous deletions within human chromosome band 9p21 in melanoma. Proc Natl Acad Sci U S A (1992) 1.58
Loss of expression of the p16/cyclin-dependent kinase inhibitor 2 tumor suppressor gene in melanocytic lesions correlates with invasive stage of tumor progression. Cancer Res (1995) 1.50
Frequent hypermethylation of p16 and p15 genes in multiple myeloma. Blood (1997) 1.35
High frequency of aberrant p16(INK4A) expression in human breast cancer. Am J Pathol (1996) 1.32
Deletions and loss of expression of p16INK4a and p21Waf1 genes are associated with aggressive variants of mantle cell lymphomas. Blood (1997) 1.22
Homozygous loss of the cyclin-dependent kinase 4-inhibitor (p16) gene in human leukemias. Blood (1994) 1.18
Gastric B-cell mucosa-associated lymphoid tissue (MALT) lymphoma. Clinicopathological study and evaluation of the prognostic factors in 143 patients. Ann Oncol (1995) 1.17
Multiple tumor-suppressor gene 1 inactivation is the most frequent genetic alteration in T-cell acute lymphoblastic leukemia. Blood (1996) 1.06
Immunohistochemical analysis of the p16INK4 cyclin-dependent kinase inhibitor in malignant mesothelioma. J Natl Cancer Inst (1995) 1.04
In vivo occurrence of p16 (MTS1) and p15 (MTS2) alterations preferentially in non-small cell lung cancers. Cancer Res (1995) 1.01
Loss of P16INK4 expression is frequent in high grade gliomas. Cancer Res (1995) 1.01
Chromosome 3 allelic losses and microsatellite alterations in transitional cell carcinoma of the urinary bladder. Am J Pathol (1996) 1.00
Flow cytometric detection of the mitochondrial BCL-2 protein in normal and neoplastic human lymphoid cells. Cytometry (1992) 0.99
Mutation rate of the CDKN2 gene in malignant gliomas. Cancer Res (1994) 0.97
Deletions and rearrangement of CDKN2 in lymphoid malignancy. Blood (1995) 0.96
Homozygous deletions of p16/MTS1 gene are frequent but mutations are infrequent in childhood T-cell acute lymphoblastic leukemia. Blood (1995) 0.96
Hypermethylation of a 5' CpG island of p16 is a frequent event in non-Hodgkin's lymphoma. Leukemia (1997) 0.95
Deletion of cyclin-dependent kinase 4 inhibitor genes P15 and P16 in non-Hodgkin's lymphoma. Blood (1995) 0.90
Mutational analysis of the CDKN2 (MTS1/p16ink4A) gene in primary B-cell lymphomas. Blood (1995) 0.87
Deletions of the cyclin-dependent kinase inhibitor genes p16INK4A and p15INK4B in non-Hodgkin's lymphomas. Blood (1995) 0.87
Homozygous loss of the MTS1/p16 and MTS2/p15 genes in lymphoma and lymphoblastic leukaemia cell lines. Br J Haematol (1995) 0.79
Refined mapping of genomic rearrangements involving the short arm of chromosome 9 in acute lymphoblastic leukemias and other hematologic malignancies. Blood (1995) 0.79
Tumours of histiocytes and accessory dendritic cells: an immunohistochemical approach to classification from the International Lymphoma Study Group based on 61 cases. Histopathology (2002) 4.22
Targeted disruption of the zetaPKC gene results in the impairment of the NF-kappaB pathway. Mol Cell (2001) 3.05
Site-specific differences in the fatty acid composition of abdominal adipose tissue in an obese population from a Mediterranean area: relation with dietary fatty acids, plasma lipid profile, serum insulin, and central obesity. Am J Clin Nutr (2001) 2.08
Mantle cell lymphoma: presenting features, response to therapy, and prognostic factors. Cancer (1998) 1.97
Thermodynamic and kinetic analysis of the SH3 domain of spectrin shows a two-state folding transition. Biochemistry (1994) 1.97
T-cell/histiocyte-rich large B-cell lymphoma is a disseminated aggressive neoplasm: differential diagnosis from Hodgkin's lymphoma. Histopathology (2002) 1.83
Characterization of the A673 cell line (Ewing tumor) by molecular cytogenetic techniques. Cancer Genet Cytogenet (2003) 1.70
Increased number of chromosomal imbalances and high-level DNA amplifications in mantle cell lymphoma are associated with blastoid variants. Blood (1999) 1.66
Pleural effusion in multiple myeloma. Chest (1994) 1.61
Is the combination of pyrazinamide plus rifampicin safe for treating latent tuberculosis infection in persons not infected by the human immunodeficiency virus? Int J Tuberc Lung Dis (2005) 1.60
Splenic marginal zone lymphoma proposals for a revision of diagnostic, staging and therapeutic criteria. Leukemia (2007) 1.51
SLC45A2: a novel malignant melanoma-associated gene. Hum Mutat (2008) 1.50
Structure of the transition state in the folding process of human procarboxypeptidase A2 activation domain. J Mol Biol (1998) 1.47
Clinical characteristics and significance of Streptococcus salivarius bacteremia and Streptococcus bovis bacteremia: a prospective 16-year study. Eur J Clin Microbiol Infect Dis (2005) 1.46
True histiocytic lymphoma (monocytic sarcoma) Am J Dermatopathol (1992) 1.45
The 12 base pair duplication/insertion alteration could be a regulatory mutation. J Med Genet (1997) 1.44
Cytotoxic/suppressor (CD8+, CD4-) cutaneous T-cell lymphoma with aggressive course. Am J Dermatopathol (1990) 1.41
Fluorescence in situ hybridization study of TEL/AML1 fusion and other abnormalities involving TEL and AML1 genes. Correlation with cytogenetic findings and prognostic value in children with acute lymphocytic leukemia. Haematologica (2001) 1.41
[Comparative study of the survival of gastric B-cell lymphoma of mucosal origin with respect to lymph node lymphoma of similar histology]. Med Clin (Barc) (1992) 1.39
[Prevalence of Factor V Leiden and the G20210A mutation of the prothrombin gene in a random group of patients with thrombotic episodes]. Sangre (Barc) (1999) 1.39
Micromachining bulk glass by use of femtosecond laser pulses with nanojoule energy. Opt Lett (2001) 1.39
Blood ammonia levels as early indicator of allograft viability in human orthotopic liver transplantation. Am J Gastroenterol (1994) 1.38
[Rapid and slow progression of the infection by the type 1 human immunodeficiency virus in a population of seropositive subjects in Madrid]. Med Clin (Barc) (1996) 1.38
PRAD-1/cyclin D1 gene overexpression in chronic lymphoproliferative disorders: a highly specific marker of mantle cell lymphoma. Blood (1994) 1.36
Classification of missense variants of unknown significance in BRCA1 based on clinical and tumor information. Hum Mutat (2007) 1.33
Update on extranodal lymphomas. Conclusions of the Workshop held by the EAHP and the SH in Thessaloniki, Greece. Histopathology (2006) 1.28
Common variations in ERCC2 are associated with response to cisplatin chemotherapy and clinical outcome in osteosarcoma patients. Pharmacogenomics J (2009) 1.28
Distinct genomic aberration patterns are found in familial breast cancer associated with different immunohistochemical subtypes. Oncogene (2007) 1.28
CraA, a major facilitator superfamily efflux pump associated with chloramphenicol resistance in Acinetobacter baumannii. Antimicrob Agents Chemother (2009) 1.27
Large B-cell lymphoma with Hodgkin's features. Histopathology (2005) 1.26
Cyclin-dependent kinase inhibitor p27KIP1 in lymphoid tissue: p27KIP1 expression is inversely proportional to the proliferative index. Am J Pathol (1997) 1.26
The molecular pathology of hereditary breast cancer. Pathobiology (2008) 1.25
Distribution of polybrominated diphenyl ethers in human umbilical cord serum, paternal serum, maternal serum, placentas, and breast milk from Madrid population, Spain. Environ Sci Technol (2007) 1.24
Invasive melanoma in Cdk4-targeted mice. Proc Natl Acad Sci U S A (2001) 1.24
FOXP3, a selective marker for a subset of adult T-cell leukaemia/lymphoma. Leukemia (2005) 1.23
Gastric B-cell mucosa-associated lymphoid tissue (MALT) lymphoma. Clinicopathological study and evaluation of the prognostic factors in 143 patients. Ann Oncol (1995) 1.17
p53 gene mutations and protein overexpression are associated with aggressive variants of mantle cell lymphomas. Blood (1996) 1.16
Prevalence of CYP2D6 gene duplication and its repercussion on the oxidative phenotype in a white population. Clin Pharmacol Ther (1995) 1.15
Differential expression of NF-kappaB pathway genes among peripheral T-cell lymphomas. Leukemia (2005) 1.14
Identification of genes involved in imatinib resistance in CML: a gene-expression profiling approach. Leukemia (2006) 1.13
p53, Rb and bcl-2 expression during the cell cycle: a study in phytohaemagglutinin stimulated lymphocytes and microwave irradiated lymphoid tissue sections. J Clin Pathol (1995) 1.13
Evaluation of single and double centrifugation tube methods for concentrating equine platelets. Res Vet Sci (2006) 1.13
Over 30% of patients with splenic marginal zone lymphoma express the same immunoglobulin heavy variable gene: ontogenetic implications. Leukemia (2012) 1.12
Increased expression of the PRAD-1/CCND1 gene in hairy cell leukaemia. Br J Haematol (1995) 1.12
Association of PHB 1630 C>T and MTHFR 677 C>T polymorphisms with breast and ovarian cancer risk in BRCA1/2 mutation carriers: results from a multicenter study. Br J Cancer (2012) 1.12
The role of the yeast plasma membrane SPS nutrient sensor in the metabolic response to extracellular amino acids. Mol Microbiol (2001) 1.10
Lhermitte-Duclos disease and Cowden disease: clinical and genetic study in five patients with Lhermitte-Duclos disease and literature review. Acta Neurochir (Wien) (2004) 1.10
Chromosomal changes pattern and gene amplification in T cell non-Hodgkin's lymphomas. Leukemia (2001) 1.08
Phenotypic expression of histocompatibility antigens in human primary tumours and metastases. Clin Exp Metastasis (1989) 1.08
Molecular heterogeneity in chronic lymphocytic leukemia is dependent on BCR signaling: clinical correlation. Leukemia (2007) 1.06
MC1R: three novel variants identified in a malignant melanoma association study in the Spanish population. Carcinogenesis (2007) 1.06
Homozygous tandem duplication within the gene encoding the beta-subunit of rod phosphodiesterase as a cause for autosomal recessive retinitis pigmentosa. Hum Mutat (1995) 1.05
Identification and characterisation of novel polymorphisms in the CYP2A locus: implications for nicotine metabolism. FEBS Lett (1999) 1.04
Splenic small B-cell lymphoma with predominant red pulp involvement: a diffuse variant of splenic marginal zone lymphoma? Histopathology (2002) 1.04
7q31-32 allelic loss is a frequent finding in splenic marginal zone lymphoma. Am J Pathol (1999) 1.03
Evidence against involvement of recoverin in autosomal recessive retinitis pigmentosa in 42 Spanish families. Hum Genet (1995) 1.02
Nitrogen movement between host and tumor in mice inoculated with Ehrlich ascitic tumor cells. Cancer Res (1984) 1.02
Estrogen and progesterone receptor gene polymorphisms and sporadic breast cancer risk: a Spanish case-control study. Int J Cancer (2006) 1.02
DIO-1 is a gene involved in onset of apoptosis in vitro, whose misexpression disrupts limb development. Proc Natl Acad Sci U S A (1999) 1.02
A haplotype containing the p53 polymorphisms Ins16bp and Arg72Pro modifies cancer risk in BRCA2 mutation carriers. Hum Mutat (2006) 1.02
Localization of the repetitive telomeric sequence (TTAGGG)n in four salmonid species. Genome (1996) 1.00
Increased risk for hepatocellular carcinoma in NAT2-slow acetylators and CYP2D6-rapid metabolizers. Pharmacogenetics (1996) 1.00
Clinical outcome in diffuse large B-cell lymphoma is dependent on the relationship between different cell-cycle regulator proteins. J Clin Oncol (1998) 1.00
Mucosal mantle cell (centrocytic) lymphomas. Histopathology (1995) 1.00
P53 protein expression in lymphomas and reactive lymphoid tissue. J Pathol (1992) 1.00
Progression to large B-cell lymphoma in splenic marginal zone lymphoma: a description of a series of 12 cases. Am J Surg Pathol (2001) 0.99
Comparative in vitro and in vivo inhibition of cytochrome P450 CYP1A2, CYP2D6, and CYP3A by H2-receptor antagonists. Clin Pharmacol Ther (1999) 0.99
Identification of MNDA as a new marker for nodal marginal zone lymphoma. Leukemia (2009) 0.99
Relationship between personality and debrisoquine hydroxylation capacity. Suggestion of an endogenous neuroactive substrate or product of the cytochrome P4502D6. Acta Psychiatr Scand (1993) 0.99
[The Pro347Leu mutation of the rhodopsin gene in a Spanish family with autosomal dominant pigmentary retinosis]. Med Clin (Barc) (1998) 0.99
Relative value of magnetic resonance spectroscopy, magnetic resonance perfusion, and 2-(18F) fluoro-2-deoxy-D-glucose positron emission tomography for detection of recurrence or grade increase in gliomas. J Clin Neurosci (2009) 0.98
Molecular analysis of the BRCA1 and BRCA2 genes in 32 breast and/or ovarian cancer Spanish families. Br J Cancer (2000) 0.98
Expression of retinoblastoma gene product (pRb) in mantle cell lymphomas. Correlation with cyclin D1 (PRAD1/CCND1) mRNA levels and proliferative activity. Am J Pathol (1996) 0.98
Lymphoma microenvironment: culprit or innocent? Leukemia (2007) 0.97
The expression of p53 protein in non-Hodgkin's lymphomas is not always dependent on p53 gene mutations. Blood (1993) 0.97
Crystal-storing histiocytosis and immunocytoma associated with multifocal fibrosclerosis. Histopathology (1998) 0.97
MicroRNA-based molecular classification of non-BRCA1/2 hereditary breast tumours. Br J Cancer (2013) 0.97
FGF receptor genes and breast cancer susceptibility: results from the Breast Cancer Association Consortium. Br J Cancer (2014) 0.96
Epstein-Barr virus microRNAs repress BCL6 expression in diffuse large B-cell lymphoma. Leukemia (2011) 0.96
Cytogenetic recombinants from a female carrying a paracentric inversion of the short arm of chromosome number 5. Hum Genet (1983) 0.96
Prevalence of BRCA1 and BRCA2 Jewish mutations in Spanish breast cancer patients. Br J Cancer (1999) 0.96
MicroRNA signatures in B-cell lymphomas. Blood Cancer J (2012) 0.95
Plasmatic homocysteine concentration and its relationship with complications associated to diabetes mellitus. Clin Chim Acta (2002) 0.95